Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) EBITDA (2016 - 2025)

Rein Therapeutics filings provide 10 years of EBITDA readings, the most recent being -$32.0 million for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 21.94% year-over-year to -$32.0 million, compared with a TTM value of -$49.9 million through Dec 2025, up 20.57%, and an annual FY2025 reading of -$49.9 million, up 20.57% over the prior year.
  • EBITDA hit -$32.0 million in Q4 2025 for Rein Therapeutics, down from -$5.6 million in the prior quarter.
  • The five-year high for EBITDA was -$1.8 million in Q2 2023, with the low at -$41.0 million in Q4 2024.
  • Median EBITDA over the past 5 years was -$6.8 million (2021), compared with a mean of -$9.1 million.
  • The sharpest move saw EBITDA soared 77.81% in 2023, then crashed 453.54% in 2024.
  • Year by year, EBITDA stood at -$6.8 million in 2021, then soared by 33.99% to -$4.5 million in 2022, then tumbled by 64.6% to -$7.4 million in 2023, then tumbled by 453.54% to -$41.0 million in 2024, then increased by 21.94% to -$32.0 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$32.0 million, -$5.6 million, and -$6.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.